Why the study?
Does lercanidipine effectively reduce blood pressure with a better safety profile regarding peripheral edema compared to other calcium channel blockers?
Does lercanidipine effectively reduce blood pressure with a better safety profile regarding peripheral edema compared to other calcium channel blockers?
Lercanidipine is an effective calcium channel blocker that significantly reduces blood pressure without affecting heart rate and has a lower incidence of peripheral edema compared to other CCBs.
May guide CCB selection in edema-prone patients; leaves open need for randomized confirmation.
Data of evidence based cardiology including results of international clinical trials on efficacy and safety of the modern calcium channel blocker (CCB), lercanidipine, are presented. Results of these trials show the firm position of lercanidipine in the modern cardiology and confirm that treatment with lercanidipine leads to significant reduction of systolic and diastolic blood pressure (BP) with no effect on heart rate (HR). Peripheral edema (the common side effect of CCBs) occurs rarer with lercanidipine treatment than this with any other CCB treatment. Lercanidipine can be recommended to patients with concomitant diseases due to its additional features.
No takes yet. Share an insight, caveat, or question.
Lukina et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: